N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
about
Potent D-peptide inhibitors of HIV-1 entryApplications of Replicating-Competent Reporter-Expressing Viruses in Diagnostic and Molecular VirologyProtease-resistant peptide design-empowering nature's fragile warriors against HIVBinding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion proteinDesign of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorHIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infectionMonocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPTCombinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formationIdentification of the HIV-1 gp41 core-binding motif--HXXNPF.Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1A cell-penetrating helical peptide as a potential HIV-1 inhibitor.Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases.IN VITRO CHEMO-PREVENTATIVE ACTIVITY OF STRELITZIA NICOLAI ARIL EXTRACT CONTAINING BILIRUBIN.Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1Origins of resistance to the HIVgp41 viral entry inhibitor T20.Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.Inhibiting HIV fusion with a beta-peptide foldamer.Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission.A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.(3aRS,9bSR)-3-(4-Chloro-phen-yl)-1-methyl-1,2,3,3a,4,9b-hexa-hydro-chromeno[4,3-b]pyrrole-3a-carbonitrileNovel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicidesBinding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infectionFrom laptop to benchtop to bedside: structure-based drug design on protein targets.Methyl 1-methyl-3-p-tolyl-1,2,3,3a,4,11c-hexa-hydro-benzo[f]chromeno[4,3-b]pyrrole-3a-carboxyl-ate.Methyl 3-(4-bromo-phen-yl)-1-methyl-1,2,3,3a,4,9b-hexa-hydro-benzo[f]chromeno[4,3-b]pyrrole-3a-carboxyl-ateMethyl 3-(4-methoxy-phen-yl)-1-methyl-1,2,3,3a,4,11b-hexa-hydro-benzo[f]chromeno[4,3-b]pyrrole-3a-carboxyl-ate.Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entryCCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
P2860
Q24675493-67BA9635-9C11-4F6E-8250-CDD84B7B5920Q26750838-D93C03E9-E5CC-45A1-910F-2946F6D6AD7FQ27010058-0255AD7D-371E-4322-9BD6-53F8BEFD42C2Q27658463-DAA131B1-3B2A-4FDF-BF08-14C674C3DF86Q27664086-EDDA0E1A-F493-4D7B-BD8B-75502A2F5B85Q27689029-28B3FD4C-D8B4-4B78-906D-B8BBCE951B26Q28485218-BEBC4961-830C-40B2-9356-E6F124477B01Q28489042-795F1624-E504-4731-8AEC-D736BD5E1CCFQ28730721-28B7467B-2756-4625-BE78-A96D16404CADQ30499941-B4A6692C-882C-4C49-944C-C8C1D1E27DA4Q30537665-A978E722-1CB5-4C85-83FE-329942529E04Q33249271-B7FCCD8D-B30A-42BF-8F7D-1AB0899ABE0BQ33253687-B9540C41-B63D-4E2B-ADCB-E07B7EA78A7FQ33262382-BF1A478C-BE2D-4C39-B6CE-CE80D9D94E78Q33269255-D14EC7DD-B8E5-4098-90D9-4DFCC1C12B8FQ33282526-93B6BABB-FCAD-4257-80EB-4A71D7850BDAQ33326188-5B303542-7237-4B94-9AB9-9D1218832D6BQ33455209-22B05B6F-14D9-47B4-99CA-B1FE44F2161BQ33624020-26884316-1A3A-4FF8-9554-4FA439FAA69CQ33638192-A9308086-D9B9-4D99-8933-3F3B8B876D08Q33770052-B998F59B-9D0D-487A-8CA8-9831FB17DB1DQ33826278-64D883DD-46AA-4511-A853-C461D0631D72Q33840121-98348996-39EE-4086-9F70-C414119FDDC6Q33860320-2ED4FE97-969B-4638-A9A7-58D4DFBF6A98Q33862300-4BFB1A38-68FE-4059-8D1F-34963221B009Q33925615-16604E00-D60D-4EE4-ADE4-F8F778D3E780Q33966639-77CECDC1-7A43-470C-AE71-C74496D9E1A2Q34021729-44623AF4-1DF6-4AFD-A538-77A52DDCBCE1Q34040567-870CCE16-0D01-4602-A013-33ECF5AF5807Q34055847-184587B6-1B64-44E5-A70E-0658A57B5367Q34057606-BE72FF14-E071-4DCE-9F68-6B34185183D6Q34062013-1577A946-7E30-499C-AEDD-309EEE0CCC34Q34153589-9EB5FBB1-E8F8-47A6-B5BC-AA61C59C1870Q34293986-0F6F7487-9FEE-4A28-B005-B45DA858B49AQ34294007-07CC46AE-4509-4E62-89B0-95198503470EQ34319700-32B111FB-BB90-4EED-81D3-6700C49A669DQ34412302-3FFB0C94-2AD3-4083-B2D7-ED989E99C734Q34412839-89860AF3-E24F-4C96-B4DF-D91CC6024DAEQ34473072-F9ABB903-A4D5-4E2E-94E0-53D22FAB8845Q34517381-C8124B28-4D09-4D44-B118-D91EFE73D70D
P2860
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
N-substituted pyrrole derivati ...... mation and block virus fusion.
@ast
N-substituted pyrrole derivati ...... mation and block virus fusion.
@en
type
label
N-substituted pyrrole derivati ...... mation and block virus fusion.
@ast
N-substituted pyrrole derivati ...... mation and block virus fusion.
@en
prefLabel
N-substituted pyrrole derivati ...... mation and block virus fusion.
@ast
N-substituted pyrrole derivati ...... mation and block virus fusion.
@en
P2093
P2860
P1476
N-substituted pyrrole derivati ...... mation and block virus fusion.
@en
P2093
Asim K Debnath
Shuwen Liu
P2860
P304
P356
10.1128/AAC.48.11.4349-4359.2004
P407
P50
P577
2004-11-01T00:00:00Z